Varicella vaccination in adults: is it cost-effective?
Varicella vaccination in adults: is it cost-effective?
复制标题
成人水痘疫苗接种：是否具有成本效益？
DOI：
10.1086/512744
复制
发表时间：
2007
期刊：
影响因子：
--
通讯作者：
Lee,GraceM
中科院分区：
文献类型：
--
作者：
Lee,GraceM
水痘是一种高度传染性疾病，在水痘疫苗可用之前，美国每年造成超过400万例病例，11，000例住院治疗和100例死亡[1]。自1996年以来，免疫实践咨询委员会建议儿童定期接种疫苗以预防水痘。在美国，儿童疫苗接种计划的后续影响是巨大的，所有年龄组（包括成人）的死亡、住院和门诊就诊率都显著下降[2-4]。成人水痘疫苗接种的最佳方法尚不确定。成年人比幼儿更有可能经历水痘疾病的严重发病率和死亡率。然而，1996年之前在美国进行的水痘人群血清阳性率估计表明，96%的20-29岁成年人和99%的30岁成年人对水痘免疫[5]。因此，成人常规疫苗接种计划的有效性可能会受到限制。另一种可能的方法是
Varicella is a highly infectious disease that caused more than 4 million cases, 11,000 hospitalizations, and 100 deaths each year in the United States before the availability of a varicella vaccine [1]. Since 1996, the Advisory Committee on Immunization Practices has recommended routine childhood vaccination to prevent varicella. The subsequent impact of a childhood vaccination program has been dramatic in the United States, with significant decreases in deaths, hospitalizations, and ambulatory visits in all age groups, including adults [2–4].The optimal approach to varicella vaccination in adults is uncertain. Adults are more likely than young children to experience severe morbidity and mortality from varicella disease. However, population seroprevalence estimates for varicella in the United States performed before 1996 suggested that 96% of 20–29-yearold adults and 99% of adults 30 years old were immune to varicella [5]. Thus, the usefulness of a routine vaccination program for adults would likely be limited. Another possible approach would be to